J&J Talc Settlement Participation Hits 87.5%: 313 Firms In, About 5,700 Claims Short of 95%

J&J talc settlement participation stands at about 87.5%: lead plaintiffs' counsel who negotiated Johnson & Johnson's $5.5 billion ovarian cancer deal told a federal magistrate judge in MDL No. 2738 earlier this month that 313 law firms representing roughly 66,500 claimants had signed on, as Law.com reported on October 19, 2026. That is the first participation number to surface publicly since the deal was announced on July 27, and it leaves the settlement about 7.5 percentage points, or roughly 5,700 claims, short of the 95% condition that must be met (or waived by J&J) before a single dollar is owed.

The figure lands in the middle of a procedural clock that has been running since late summer. The District of New Jersey has frozen the largest Multidistrict Litigation (MDL) in the federal system and ordered the negotiators to report on sign-ups every two weeks. Johnson & Johnson's chief financial officer told investors on October 13 that the company is "trending to meet" the threshold. And on the same day Law.com published the count, it reported that another talc trial had opened, this one in Boston, over a mesothelioma death that the ovarian deal was never designed to resolve. What follows explains what the 87.5% figure does and does not establish, how far the deal is from closing, what happens if it stalls, and what the number means for holdout firms, participating firms, funders and the defense.

How many claimants have signed up for the J&J talc settlement?

About 66,500 claimants, represented by 313 law firms, had signed on as of the report to the court described by Law.com. Lead plaintiffs' counsel put that at about 87.5% of total claims. The exact filing date of that report has not been made public; Law.com describes it as made "earlier this month," which places it within the series of status updates the court began requiring on September 15.

The 87.5% figure is internally consistent with Johnson & Johnson's own perimeter. The company said in July that the deal covers roughly 76,000 ovarian talc claims pending in state and federal court, which it described as nearly all of the remaining ovarian claims. Divide 66,500 by 76,000 and the result is 87.5% exactly. That matters, because it indicates the negotiators are measuring against the company's all-courts denominator, not against the federal MDL count alone. The Judicial Panel on Multidistrict Litigation (JPML) reported 69,340 actions pending in MDL 2738 on October 1, 2026; the remainder of the 76,000 sits in state courts, principally New Jersey's multicounty litigation and other state dockets.

Three features of the number deserve emphasis before anyone treats it as a scoreboard:

• It counts claims through firms. The 313 figure is the number of law firms whose inventories have been committed. The condition J&J wrote is satisfied by "express participation" of lead plaintiff firms, not by individual ballots.
• It is a reported figure, not a verified one. No claims administrator has published an audited count, and the court has not made any finding about participation.
• It is a snapshot. The court-ordered reports recur every two weeks. A figure reported in early October may already be higher.

Has the J&J talc settlement reached 95% participation?

No. At 87.5%, J&J talc settlement participation is below the 95% condition precedent that Johnson & Johnson attached to the deal on July 27, 2026, and the settlement has not taken effect. Until the condition is satisfied or the company elects to waive it, the agreement creates no payment obligation.

The company's public posture is optimistic. On the October 13 third-quarter earnings call, chief financial officer Joseph Wolk said, "We are trending to meet the 95% threshold," and the company recorded a $5.519 billion pre-tax litigation charge in the quarter for the proposed resolution. A company does not typically accrue the full value of a deal it expects to fail, so the accounting and the 87.5% figure point in the same direction: substantial momentum, no closing.

How many more claims does J&J need to reach 95%?

Roughly 5,700 more claims, assuming the 76,000-claim denominator the 87.5% figure implies. Ninety-five percent of 76,000 is 72,200 claims; 66,500 are reported in; the difference is about 5,700. Put differently, about 9,500 claims remain outside the deal, and the settlement can absorb only about 3,800 holdouts in total before the condition fails.

Measure	Claims	Share of ~76,000
Claims inside the deal perimeter (J&J, July 27, 2026)	~76,000	100%
Participation required by the condition	~72,200	95%
Participation reported to the court (313 firms)	~66,500	87.5%
Additional claims needed to reach 95%	~5,700	7.5%
Claims not yet signed	~9,500	12.5%
Maximum holdouts the condition tolerates	~3,800	5%
Federal MDL 2738 actions pending (JPML, October 1, 2026)	69,340	n/a (federal only)

Two cautions apply to that arithmetic. First, the denominator is not static: claims are dismissed, consolidated or deduplicated as the inventories are reconciled, and new filings continue (the federal docket grew from 69,250 on September 1 to 69,340 on October 1). Second, the remaining 9,500 claims are not evenly distributed. If they are concentrated in a handful of inventories, the closing question is a negotiation with a few firms, not a canvass of thousands of claimants.

Who is counted: firms, not individual claimants

The single most important structural fact about J&J talc settlement participation is that the count runs through lawyers. Johnson & Johnson's announcement conditioned the resolution on "the express participation of the lead plaintiff firms" in the ovarian talc litigation representing at least 95% of remaining claims. A claimant whose firm signs is counted on the participating side, subject to the claimant's own later consent; a claimant whose firm holds out is counted on the other side.

That design converts what looks like a 76,000-person referendum into a negotiation among inventory holders. Law.com's figure of 313 participating firms suggests the remaining 12.5% is spread across firms that have not yet committed, and the economics of those holdouts differ sharply from the economics of the firms already in.

It also creates a two-stage consent problem. A firm's commitment satisfies J&J's condition, but it does not bind any individual client. Under ABA Model Rule 1.8(g) and New Jersey's counterpart, a lawyer who represents multiple clients may not participate in an aggregate settlement of their claims unless each client gives informed consent, in a writing signed by the client, after disclosure of the existence and nature of all the claims involved and of each person's participation. A participating firm therefore has to deliver individual releases beneath its commitment. Any claimant who refuses the matrix value offered can, in principle, decline and continue litigating, although that claimant then faces the show-cause order described below.

This is the same architecture mass arbitration practitioners will recognize from an Aggregate Settlement (Mass Arbitration): the respondent negotiates with Coordinated Counsel, and counsel then has to obtain individual client sign-off underneath the deal.

What the MDL 2738 court is doing with the participation reports

The court's role is supervisory, not approving. On August 28, 2026, the District of New Jersey entered an online docket entry finding good cause "to require regular updates as to the status of communications with claimants, claimant participation, and the settlement process," as reported by HarrisMartin. Negotiation Counsel's first update was due September 15, 2026, with subsequent updates every two weeks until the court orders otherwise. Deadlines in the MDL remain held in abeyance.

None of that turns the deal into a Class Action settlement. There is no certified Settlement Class, no Rule 23 fairness hearing, no Class Notice and no court-administered opt-out. MDL 2738 is a pretrial coordination device under 28 U.S.C. § 1407; each case remains an individual case, and an inventory resolution of this kind is, legally, tens of thousands of individual settlements executed in parallel and typically funded through a Qualified Settlement Fund (QSF) run by a Claims Administrator. What the court can do is keep the litigation still, require reports and decide when the pause has gone on long enough.

Date	Event
March 31, 2025	Bankruptcy court rejects the Red River Talc prepackaged plan (reported at about $9 billion); J&J returns to the tort system
July 22, 2026	Magistrate Judge Rukhsanah L. Singh orders ovarian plaintiffs to show cause why remaining claims should not be dismissed for failure to prove specific causation
July 27, 2026	J&J announces $5.5 billion proposal covering about 76,000 ovarian claims, conditioned on 95% participation
August 28, 2026	D.N.J. docket entry requires regular participation updates; deadlines held in abeyance
September 15, 2026	First Negotiation Counsel update due; further updates every two weeks
October 1, 2026	JPML reports 69,340 actions pending in MDL 2738
October 13, 2026	J&J books $5.519 billion pre-tax talc charge; CFO says company is "trending to meet" 95%
Early October 2026	Counsel report 313 firms, about 66,500 claimants, about 87.5% participation
October 19, 2026	Law.com reports the figure and the opening of the Haddad mesothelioma trial in Boston
November 19, 2026	Plaintiffs' response to the show-cause order due if the litigation resumes

What happens if the J&J talc settlement misses 95%?

If the threshold is neither met nor waived, the agreement does not take effect, no money moves, and the MDL restarts from a position that is materially worse for claimants than it was a year ago. The abeyance would lift, the deadlines would return, and the plaintiffs' response to the July 22 show-cause order, currently due November 19, 2026, would become the central event in the docket.

That order followed the withdrawal of plaintiffs' Specific Causation experts in bellwether cases, which is the reason J&J could demand 95% in the first place. Specific causation is the individual-case element: whether talc caused this claimant's ovarian cancer. General Causation, the broader question of whether talc can cause ovarian cancer at all, is a separate hurdle that the federal court has addressed in earlier Daubert Challenge rounds. A failed deal does not return the parties to a neutral starting line; it returns them to a docket in which the defense has a pending dismissal vehicle aimed at the element plaintiffs most recently declined to defend.

There is also a calendar problem. The show-cause response deadline and the biweekly reporting cadence are on a collision course. If the count is still materially short of 95% by mid-November, plaintiffs' leadership will face a choice between filing a substantive response, which signals that the deal may not close, and seeking a further extension, which requires the court to keep the abeyance in place. Either filing will be a stronger signal of the deal's health than any interim participation number.

Can J&J waive the 95% participation threshold?

Yes, in principle. A condition precedent that exists for one party's benefit can generally be waived by that party, and the 95% condition exists for Johnson & Johnson's benefit: it protects the company from paying billions while a large residual inventory remains in the tort system. Whether the agreement itself contains an express waiver clause, a cure period or a reduced-fund fallback has not been made public, and those terms should not be assumed.

What can be said is that waiver is a unilateral option, not a plaintiffs' remedy. Holdout firms cannot force the deal to close by arguing that 87.5% or 92% is close enough; only J&J can decide to accept less than 95%. Commentary on the Lawsuit Information Center site has suggested it is very unlikely J&J will demand strict compliance if participation comes reasonably close. That is an informed opinion from a plaintiffs' firm, not a company statement, and the company has publicly said only that it is trending to meet the threshold.

The incentives cut both ways. A company that has already booked a $5.519 billion charge, told investors the deal is on track and pressed a causation ruling into a dismissal threat has strong reasons to close at something near 95% rather than restart the litigation. But it also has a reason to keep the condition formally in place for as long as possible, because the threat of non-closure is the main lever it holds over the remaining firms.

Why the last 7.5% is the hardest

Participation thresholds produce a predictable endgame. As the count rises toward the threshold, each remaining claim becomes more valuable to the defendant, because each one is closer to being the claim that decides whether the deal closes. That creates a holdout premium: a firm sitting on several hundred claims at 93% has far more leverage than the same firm had at 70%.

The firms still outside the deal are also self-selected. They are more likely to include firms that believe their clients have stronger individual evidence, firms with state-court cases on more favorable trial calendars, firms whose clients have objected to projected matrix values, and firms with financing or fee structures that make an uncapped but delayed payment schedule less attractive. Several of those reasons are durable. A firm whose clients reject the Settlement Matrix cannot sign on their behalf regardless of price.

Against that, the remaining firms face the same downside as everyone else if the deal fails: the show-cause order applies to the whole federal inventory, not only to participating claims. A holdout strategy is rational only if the firm believes either that J&J will waive the threshold to close without it or that its clients' cases are strong enough to survive a specific-causation challenge without the experts who were withdrawn. For most remaining inventories, the second proposition is the harder one to defend.

Is the J&J talc settlement $5.5 billion or $5.8 billion?

Johnson & Johnson's own announcement and its July 27, 2026 Form 8-K describe a $5.5 billion commitment, and the company's third-quarter charge was $5.519 billion. Law.com's October 19 headline refers to a "$5.8B settlement," and no primary source located for this article supports the higher figure; it should be read as a press characterization rather than a revised term. Neither number is a cap. The deal uses an uncapped, point-based matrix, and Christopher Seeger, who helped negotiate it, has been reported as estimating that total payments could exceed $7 billion depending on how many claims qualify and at what tier.

Term	As stated by Johnson & Johnson (July 27, 2026)
Company commitment	$5.5 billion
Claims in perimeter	About 76,000 ovarian talc claims in state and federal court
Condition precedent	Express participation by lead plaintiff firms representing at least 95% of remaining claims
First payment	No more than $3 billion, in 2027
Later payments	None due before 2028
Aggregate cap	None; matrix-based valuation
Excluded	Mesothelioma claims; claims not yet on file
Court approval	Not required; not a Rule 23 settlement

Per-claim values have not been published. Ranges circulating on claimant-acquisition sites are estimates, not matrix tiers, and should be treated accordingly.

Does the talc settlement cover mesothelioma claims?

No. The July proposal resolves ovarian cancer claims only; mesothelioma claims, which allege asbestos contamination of talc products and are tried under different proof, are outside it. That is why talc trials continue even as the ovarian deal approaches its threshold, and why the second half of Law.com's October 19 report matters to anyone pricing J&J's residual exposure.

What is the Haddad talc trial in Boston about?

The trial, in Suffolk County Superior Court in Massachusetts, concerns Winifred Haddad, a nurse and mother of four sons who was diagnosed with mesothelioma at 66 and died in 2020. According to Law.com, plaintiffs' counsel Aaron Chapman of Dean Omar Branham Shirley told jurors in opening statements that Johnson & Johnson's baby powder caused her cancer and death. J&J's trial counsel, Will Stute of King & Spalding, challenged the plaintiffs' experts and what caused her death. No verdict had been reported as of October 21, 2026.

Massachusetts juries have been receptive to mesothelioma talc claims against J&J in recent trials:

Case (Massachusetts)	Date	Result reported
Paluzzi	June 2025	$8 million ($5 million past and $3 million future pain and suffering); negligence and breach of warranty
Lovell	July 2025	$42.6 million, including $16 million to the spouse for loss of consortium; reported as the largest mesothelioma verdict in state history
Haddad	Trial opened October 2026	Pending

Those results do not predict the Haddad outcome; mesothelioma trials turn heavily on exposure history and alternative-source evidence, which is precisely where J&J's defense concentrated in its opening. But they explain why the ovarian settlement, even at 100% participation, does not end Johnson & Johnson's talc docket. The company still faces the mesothelioma stream, and claims not yet filed are outside the deal as well. Achieving finality over future claims was what the Texas Two-Step and a Section 524(g) Trust-style channeling injunction were designed to deliver in bankruptcy; a negotiated inventory settlement in the tort system cannot do it.

When will talc settlement payments be made?

Not before 2027, and only after the participation condition is satisfied or waived. Under the July terms, Johnson & Johnson's first payment is capped at $3 billion in 2027, with no further payments due before 2028. Claimants should also expect the usual deductions and holdbacks between gross award and net check: attorneys' Contingency Fee percentages, case expenses, any Common Benefit Fund assessment set in the MDL, and resolution of Medical Lien claims by Medicare, Medicaid and private insurers.

The sequencing matters for individual claimants. A firm's signature on the participation agreement is the first step; individual releases, documentation of diagnosis and product use, matrix scoring and lien resolution follow. Even an on-time closing in late 2026 would leave most individual payments months away.

What the 87.5% figure does not tell us

The number is useful, but several things a practitioner would want to know remain outside the public record, and none of them should be filled in by inference.

• The exact report date and its place in the sequence. Law.com describes the figure as reported "earlier this month." Without the date, it is not possible to say whether participation rose from the September 15 report to this one, or by how much.
• Concentration of the remaining inventory. The figure gives a firm count for the participants (313) but none for the holdouts. Whether the remaining 9,500 or so claims sit with five firms or fifty determines whether closing is a negotiation or a campaign.
• Federal versus state split. The 87.5% is measured against an all-courts denominator. How many of the unsigned claims are in MDL 2738, and therefore exposed to the show-cause order, versus in state courts with their own calendars, has not been reported.
• Deadline for the condition. No public source states the date by which the 95% threshold must be reached, or the date on which J&J's right to walk away lapses.
• Claims administrator and matrix tiers. No administrator has been publicly named and no point values have been published, so no reliable per-claim figure exists.

Each of those gaps also identifies what to watch. In the coming weeks, the most informative signals are likely to be (1) a further reported participation figure, especially one that crosses 90%; (2) any filing touching the November 19 show-cause deadline, whether an extension request or a substantive response; (3) any order modifying the abeyance or the reporting cadence; (4) a public statement from Johnson & Johnson on satisfaction or waiver of the condition; and (5) the appointment of a claims administrator or special master for allocation, which would signal that the parties are building the payment infrastructure that follows a closing.

The state-court picture deserves its own attention. New Jersey's multicounty talc litigation had its leadership disrupted earlier in 2026, and state dockets elsewhere carry their own trial settings. A state-court claimant whose case is set for trial in the near term holds a different kind of leverage from a federal claimant whose case is frozen in an MDL awaiting a causation ruling, and those differences will shape which inventories come in last.

The mass arbitration parallel: a blow-up provision in tort form

Lawyers who negotiate aggregate resolutions of mass arbitration inventories will recognize the 95% condition immediately. It performs the same function as a Blow-Up Provision: the respondent pays to buy peace across an inventory and reserves the right to walk away if too few claimants accept, because a partial resolution funds the strongest residual cases and the most aggressive remaining counsel.

The differences are instructive. Mass arbitration settlement agreements commonly specify the acceptance window, the walk-away percentage, a waiver right for the respondent and sometimes a sliding scale that shrinks the fund instead of voiding the deal. Only the percentage has been made public in the talc deal. The court-ordered biweekly reports perform some of the transparency function that a defined acceptance window would provide, but they do not tell outsiders when J&J's option to walk away expires or whether a reduced-fund fallback exists.

There is a second lesson running the other way. In mass arbitration, respondents learned that publicizing a participation count can strengthen holdouts. The same tension exists here: a precise, public running total gives each remaining firm a measure of its own leverage. That may explain why the figure surfaced through press reporting of a status communication rather than through any formal public filing of a number.

What the 87.5% figure means for the people involved

What it means for holdout firms

The window for extracting a premium is real but narrowing. Every two-week report that shows participation rising reduces the marginal value of each remaining inventory and increases the risk that J&J closes by waiver at a level that leaves holdouts in a restarted MDL facing the show-cause order alone. Firms outside the deal should have a documented, client-by-client basis for that decision, because the downside scenario concentrates on them.

What it means for participating firms

The firm-level commitment is the easy part. The harder work is the individual consent process: informed, written client consent to the aggregate terms with the disclosures the aggregate-settlement rule requires, verification of diagnosis and product-use evidence, and early engagement with lienholders. Firms that signed early should also anticipate client questions about the gap between the reported $5.5 billion, the $5.8 billion in headlines and Seeger's reported $7 billion estimate, and about why no one will be paid in 2026.

What it means for litigation funders and lienholders

The 87.5% figure is the first data point that allows serious modeling of closing probability, but it is not a closing. Funders with exposure to talc inventories should expect distributions no earlier than 2027 even in the best case, and lienholders should expect resolution requests through a centralized process once a claims administrator is in place. Third-Party Litigation Funding agreements whose economics depend on 2026 payouts are already off schedule under the July terms.

What it means for defendants in other mass torts

J&J's approach (a dispositive causation ruling first, then an uncapped matrix conditioned on near-unanimity, then court-supervised but not court-approved participation reporting) is now a visible template for resolving a mass tort outside bankruptcy. Other defendants whose bankruptcy routes have been narrowed by the Supreme Court's 2024 Purdue Pharma decision, which bars nonconsensual third-party releases in Chapter 11, will study whether it closes and at what participation level.

FAQ

How many claimants have signed up for the J&J talc settlement?

About 66,500 claimants represented by 313 law firms, or roughly 87.5% of claims, according to lead plaintiffs' counsel's report to a federal magistrate judge earlier in October 2026, as reported by Law.com on October 19.

Has the J&J talc settlement reached 95% participation?

No. Reported J&J talc settlement participation is about 87.5%, below the 95% condition. The deal has not taken effect, although J&J's CFO said on October 13, 2026 that the company is "trending to meet" the threshold.

What happens if the J&J talc settlement misses 95%?

Unless J&J waives the condition, the deal does not take effect, the MDL 2738 abeyance can be lifted, and plaintiffs must answer the July 22, 2026 show-cause order on specific causation, with a response currently due November 19, 2026.

Does the J&J talc settlement cover mesothelioma claims?

No. It covers ovarian cancer claims only. Mesothelioma claims, such as the Haddad case now on trial in Suffolk County Superior Court in Boston, are excluded, as are claims not yet filed.

When will talc settlement payments be made?

No earlier than 2027. The first payment is capped at $3 billion in 2027, with nothing further due before 2028, and only after the participation condition is satisfied or waived.

Is the talc settlement $5.5 billion or $5.8 billion?

Johnson & Johnson's announcement and SEC filing state $5.5 billion; a Law.com headline used $5.8 billion. Neither is a cap: the matrix is uncapped, and lead negotiator Christopher Seeger has reportedly estimated total payments could exceed $7 billion.